PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
242.97%
Revenue growth above 1.5x CRON.TO's 23.03%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
191.95%
Positive gross profit growth while CRON.TO is negative. John Neff would see a clear operational edge over the competitor.
-318.21%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-318.21%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-299.52%
Negative net income growth while CRON.TO stands at 224.95%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-295.00%
Negative EPS growth while CRON.TO is at 217.86%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-295.00%
Negative diluted EPS growth while CRON.TO is at 912.50%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
2.15%
Share count expansion well above CRON.TO's 1.28%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.34%
Slight or no buyback while CRON.TO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-1249.62%
Negative OCF growth while CRON.TO is at 54.35%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-27.33%
Negative FCF growth while CRON.TO is at 33.44%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
28238.49%
5Y CAGR of 28238.49% while CRON.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
545.67%
3Y revenue/share CAGR under 50% of CRON.TO's 1828.11%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-187.04%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-89.89%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-395.23%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-1405.06%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-592.17%
Negative 5Y net income/share CAGR while CRON.TO is 17508.70%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1081.80%
Negative 3Y CAGR while CRON.TO is 66090.25%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4146.76%
Equity/share CAGR of 4146.76% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2334.22%
Below 50% of CRON.TO's 5664.00%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
298.88%
Below 50% of CRON.TO's 1219.50%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.94%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
115.87%
Inventory growth well above CRON.TO's 5.44%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.21%
Negative asset growth while CRON.TO invests at 2.71%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-5.72%
We have a declining book value while CRON.TO shows 71.78%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
41.69%
Debt shrinking faster vs. CRON.TO's 129.61%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
-63.20%
Our R&D shrinks while CRON.TO invests at 10.87%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
90.27%
SG&A growth well above CRON.TO's 34.00%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.